Balaxi Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Balaxi Pharmaceuticals Ltd reported a 16.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 21.2%.
• Its expenses for the quarter were down by 17.2% QoQ and 16.7% YoY.
• The net profit decreased 27.6% QoQ and decreased 95.4% YoY.
• The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 0.04 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Balaxi Pharmaceuticals Ltd is a company that operates within the pharmaceutical industry, specializing in the manufacturing, marketing, and distribution of pharmaceutical products. While specific recent developments and product details are not provided, companies in this sector typically engage in the production of generic medications, active pharmaceutical ingredients, and other healthcare-related products. The pharmaceutical industry is characterized by its focus on innovation, regulatory compliance, and extensive research and development efforts. It is important to note that detailed information about Balaxi Pharmaceuticals Ltd's specific products or any recent strategic initiatives is not available in the provided data.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Balaxi Pharmaceuticals Ltd reported a total income of ₹57.76 crores. This represents a decrease of 16.3% quarter-over-quarter (QoQ) from the previous quarter (Q1FY26), where the total income was ₹68.97 crores. Additionally, there is a notable year-over-year (YoY) decline of 21.2% from Q2FY25, when the total income was ₹73.27 crores. The decline in revenue both sequentially and annually may reflect various factors impacting the company's sales performance during this period.

Profitability

The Profit Before Tax (PBT) for Balaxi Pharmaceuticals Ltd in Q2FY26 was ₹1.38 crores, showing a significant improvement of 53.3% QoQ compared to ₹0.90 crores in Q1FY26. However, when compared to Q2FY25, where the PBT was ₹5.56 crores, there is a substantial YoY decline of 75.2%. The tax expense for Q2FY26 was ₹1.17 crores, reflecting an increase of 91.8% QoQ and 20.6% YoY. Consequently, the Profit After Tax (PAT) for Q2FY26 was ₹0.21 crores, a decrease of 27.6% QoQ from ₹0.29 crores in Q1FY26, and a steep decline of 95.4% YoY from ₹4.59 crores in Q2FY25. The Earnings Per Share (EPS) for the quarter stood at ₹0.04, down from ₹0.05 in Q1FY26 and ₹0.84 in Q2FY25, indicating a reduction of 20.0% QoQ and 95.2% YoY.

Operating Metrics

Total expenses for Balaxi Pharmaceuticals Ltd in Q2FY26 amounted to ₹56.38 crores, marking a decrease of 17.2% from ₹68.06 crores in Q1FY26. Compared to the same quarter last year (Q2FY25), total expenses decreased by 16.7% from ₹67.70 crores. The reduction in expenses QoQ and YoY may reflect cost management initiatives or changes in operational activities. The financial data provide insights into the company's operational efficiency and its ability to manage costs relative to its revenue generation during the reported period.